International Journal of Biology
(IJB)

Antibiotic Resistance Mechanisms and Strategies for Combating Resistance in Germany

Felix Carl

IPRJB
INTERNATIONAL PEER REVIEWED JOURNAL AND BOOK PUBLISHING

International Journal of Biology

ISSN 2710-3765 (Online)
Vol 4, Issue 1, No.4, pp 35 - 45, 2024

www.iprjb.org

Antibiotic Resistance Mechanisms and Strategies for Combating Resistance in Germany

Felix Carl
University of Freiburg

Article History

Received 17th February 2024

Received in Revised Form 20th March 2024

Accepted 21st April 2024

Abstract

Purpose: The aim of the study was to explore antibiotic resistance mechanisms and strategies for combating resistance in Germany

Methodology: This study adopted a desk methodology. A desk study research design is commonly known as secondary data collection. This is basically collecting data from existing resources preferably because of its low cost advantage as compared to a field research. Our current study looked into already published studies and reports as the data was easily accessed through online journals and libraries.

Findings: antibiotic resistance represents a complex and evolving challenge to public health in Germany. Mechanisms such as efflux pumps, mobile genetic elements, and enzymatic degradation contribute to the resilience of bacteria against antibiotics. However, strategic interventions have been identified to combat resistance effectively. Exploration of alternative therapies like bacteriophage therapy offers promising avenues for addressing antibiotic-resistant infections, especially in light of increasing resistance rates.

Unique Contribution to Theory, Practice and Policy: Evolutionary theory of antibiotic resistance & Game Theory in Antibiotic Stewardship may be used to anchor future studies on antibiotic resistance mechanisms and strategies for combating resistance in Germany. Implement antimicrobial stewardship programs across healthcare settings to optimize antibiotic use. These programs should involve prescriber education, antibiotic guidelines, and regular audits to promote appropriate prescribing practices and minimize unnecessary antibiotic exposure. Prioritize infection prevention measures, including hand hygiene, environmental cleaning, and infection control protocols, to reduce the spread of resistant pathogens within healthcare facilities and communities. Enact policies to regulate the use of antibiotics in human health, veterinary medicine, and agriculture. This includes restrictions on antibiotic use in food production, bans on over-the-counter antibiotic sales, and incentives for the development of new antibiotics.

Keywords: *Antibiotic Resistance, Mechanisms, Strategies, Combating*

INTRODUCTION

Antibiotic resistance mechanisms have become a critical global health issue, threatening the effectiveness of antibiotics in treating bacterial infections. One common mechanism is the acquisition of resistance genes through horizontal gene transfer, which enables bacteria to develop resistance to multiple antibiotics simultaneously. For example, in the United States, the prevalence of multidrug-resistant bacteria has been steadily increasing over the past decade. According to a study by Centers for Disease Control and Prevention (CDC), the proportion of Enterobacteriaceae isolates resistant to carbapenems, a last-line class of antibiotics, increased from 1.2% in 2001 to 4.2% in 2011 (Jones, 2015).

Another mechanism of antibiotic resistance involves the overexpression of efflux pumps, which actively remove antibiotics from bacterial cells, thereby reducing their effectiveness. In Japan, the emergence of fluoroquinolone-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), has become a significant concern. A study published in the Journal of Infection and Chemotherapy reported that the proportion of MRSA isolates resistant to fluoroquinolones increased from 46.4% in 2000 to 62.3% in 2010 (Takizawa, 2013). These trends underscore the urgent need for enhanced surveillance and antimicrobial stewardship efforts to combat antibiotic resistance in developed economies.

In developing economies, antibiotic resistance poses unique challenges due to factors such as limited access to healthcare, poor sanitation infrastructure, and widespread antibiotic misuse. In sub-Saharan Africa, for instance, the prevalence of antibiotic-resistant pathogens has been on the rise. A study conducted in Nigeria found high rates of resistance among clinical isolates of Escherichia coli and Klebsiella pneumoniae to commonly used antibiotics such as ampicillin and ciprofloxacin (Olowe, 2017). Similarly, in South Africa, the emergence of extensively drug-resistant tuberculosis (XDR-TB) strains has become a major public health concern, with a study reporting a 7.3% increase in XDR-TB cases from 2011 to 2015 (Said, 2018). Addressing antibiotic resistance in these regions requires concerted efforts to improve healthcare infrastructure, promote appropriate antibiotic use, and strengthen surveillance systems to monitor resistance patterns.

In developed economies such as the United States and the United Kingdom, antibiotic resistance is a growing concern with significant public health implications. One prominent example of antibiotic resistance is the rise of methicillin-resistant Staphylococcus aureus (MRSA) infections in healthcare settings. According to data from the U.S. Centers for Disease Control and Prevention (CDC), the incidence of invasive MRSA infections decreased by approximately 17% from 2005 to 2011, but remained stable thereafter, highlighting the persistent challenge of MRSA in healthcare settings (CDC, 2019). Similarly, in the UK, surveillance data from Public Health England (PHE) showed that while there was a decline in MRSA bloodstream infections between 2012 and 2016, there has been a recent increase in cases, indicating ongoing transmission and the need for continued vigilance (PHE, 2019).

Another concerning trend in developed economies is the emergence of multidrug-resistant Gram-negative bacteria, such as carbapenem-resistant Enterobacteriaceae (CRE). In the United States, CRE infections have been associated with high mortality rates, posing a serious threat to patient safety in healthcare settings. CDC surveillance data revealed a nearly 10-fold increase in the proportion of Enterobacteriaceae isolates resistant to carbapenems from 2001 to 2011, with CRE becoming increasingly common in both healthcare and community settings (CDC, 2013). Similarly, in the UK, the spread of CRE has led to outbreaks in healthcare facilities, prompting enhanced infection control measures and antimicrobial stewardship efforts to curb transmission (Johnson, 2017). These examples underscore the urgent need for coordinated national and international efforts to combat antibiotic resistance and preserve the effectiveness of existing antibiotics.

In developing economies, antibiotic resistance poses significant challenges due to factors such as limited healthcare resources, inadequate infection control measures, and widespread antibiotic misuse. One example of antibiotic resistance in developing economies is the spread of extensively drug-resistant tuberculosis (XDR-TB), which is resistant to first-line and second-line tuberculosis drugs. In countries like India, XDR-TB has become a major public health concern, with studies reporting high rates of resistance to multiple antibiotics among tuberculosis patients. A study published in PLOS ONE found that approximately 6% of multidrug-resistant tuberculosis (MDR-TB) cases in India were classified as XDR-TB, highlighting the urgent need for improved TB diagnostics and treatment strategies (Dalal, 2016).

Another example is the emergence of multidrug-resistant Gram-negative bacteria in healthcare settings in developing economies. In countries like Brazil, nosocomial infections caused by multidrug-resistant bacteria, such as Acinetobacter baumannii and Klebsiella pneumoniae, have become increasingly common, leading to higher morbidity and mortality rates among patients. A study conducted in a Brazilian hospital found that approximately 63% of Acinetobacter baumannii isolates were resistant to carbapenems, a last-line class of antibiotics, highlighting the urgent need for enhanced infection control measures and antimicrobial stewardship programs (Martins, 2018). These examples underscore the importance of addressing antibiotic resistance as a global health priority, with particular attention to the unique challenges faced by developing economies.

In sub-Saharan Africa, antibiotic resistance presents unique challenges due to factors such as limited healthcare infrastructure, inadequate sanitation facilities, and high burden of infectious diseases. One significant example is the spread of multidrug-resistant (MDR) bacteria among patients in healthcare settings. In countries like Nigeria, studies have documented high rates of resistance to commonly used antibiotics among clinical isolates of bacteria such as Escherichia coli and Klebsiella pneumoniae. A study conducted in a tertiary care hospital in Nigeria found that over 70% of Klebsiella pneumoniae isolates were resistant to third-generation cephalosporins, highlighting the urgent need for improved infection control practices and antimicrobial stewardship programs (Olowe, 2017).

Another concerning trend in sub-Saharan Africa is the emergence of antibiotic resistance in foodborne pathogens, which poses risks to both human health and food security. In countries like Kenya, studies have reported high rates of antibiotic resistance among foodborne bacteria such as Salmonella and Escherichia coli. A study published in BMC Microbiology found that over 80% of Salmonella isolates from poultry samples in Kenya were resistant to multiple antibiotics, including commonly used drugs such as ampicillin and tetracycline (Kariuki, 2015). These findings underscore the importance of implementing comprehensive surveillance systems and promoting responsible antibiotic use in both healthcare and agricultural settings to address the growing threat of antibiotic resistance in sub-Saharan economies.

In sub-Saharan Africa, antibiotic resistance represents a multifaceted challenge due to factors such as limited healthcare infrastructure, socioeconomic disparities, and high burden of infectious diseases. One significant aspect of this challenge is the emergence of multidrug-resistant (MDR) strains of tuberculosis (TB). Sub-Saharan Africa bears a disproportionate burden of TB, with high rates of MDR-TB reported in several countries. For instance, a study conducted in Ethiopia found that approximately 14% of newly diagnosed TB patients and 47% of previously treated TB patients had MDR-TB, indicating a significant level of resistance to first-line TB drugs (Tadesse, 2017). The emergence of MDR-TB strains underscores the need for strengthened TB control efforts, including improved diagnostics, patient management, and infection control measures.

Additionally, the prevalence of antibiotic resistance among enteric pathogens in sub-Saharan Africa poses a major public health concern, particularly in the context of diarrheal diseases. Studies have documented high rates of resistance to common antibiotics among bacteria such as Salmonella and Shigella, which are leading causes of diarrheal illness in the region. For example, a study conducted in Ghana found that over 70% of Salmonella isolates from diarrheal stool samples were resistant to multiple antibiotics, including ampicillin, trimethoprim-sulfamethoxazole, and ciprofloxacin (Krumkamp, 2015). The widespread resistance observed in enteric pathogens highlights the importance of promoting access to clean water, sanitation, and hygiene practices, as well as judicious use of antibiotics to prevent the further spread of resistant strains in sub-Saharan Africa.

Strategies for combating antibiotic resistance encompass a multifaceted approach that addresses both the underlying mechanisms driving resistance and the factors contributing to its spread. One key strategy is the development of novel antibiotics and alternative therapies that target bacterial vulnerabilities while minimizing the risk of resistance emergence. This includes the exploration of new drug targets, such as essential bacterial enzymes or virulence factors, as well as the repurposing of existing drugs or the use of combination therapies to enhance efficacy and prevent resistance (Golkar, 2014). Additionally, efforts to improve antibiotic stewardship and promote rational antibiotic use are essential for preserving the effectiveness of existing antibiotics. This involves implementing policies and guidelines to optimize antibiotic prescribing practices in healthcare settings, as well as educating healthcare professionals and the public about the importance of appropriate antibiotic use and the consequences of misuse (Laxminarayan, 2013).

Another crucial strategy is the implementation of infection prevention and control measures to reduce the transmission of resistant bacteria in healthcare facilities and the community. This includes practices such as hand hygiene, environmental cleaning, and isolation of patients with resistant infections to prevent outbreaks and minimize the spread of resistance (Allegranzi, 2016). Furthermore, efforts to strengthen surveillance systems and enhance antimicrobial resistance monitoring are essential for tracking resistance trends, identifying emerging threats, and informing public health interventions. This involves establishing national and global surveillance networks to monitor antibiotic resistance in bacteria of public health significance, as well as investing in laboratory capacity building and data sharing mechanisms to facilitate timely detection and response to outbreaks (WHO, 2019).

Problem statement

Antibiotic resistance poses a significant global health threat, as bacterial pathogens increasingly develop mechanisms to evade the effects of antibiotics, rendering many commonly used drugs ineffective. The emergence and spread of antibiotic resistance mechanisms not only complicate the treatment of infectious diseases but also undermine decades of medical progress, leading to increased morbidity, mortality, and healthcare costs. Moreover, the current pace of antibiotic discovery and development lags behind the rate at which resistance is evolving, exacerbating the challenge of combating resistant infections. Therefore, there is an urgent need to understand the molecular mechanisms driving antibiotic resistance and to develop innovative strategies for preventing and controlling resistance in order to safeguard public health and preserve the effectiveness of antibiotics for future generations (Ventola, 2015).

Theoretical Review

Evolutionary Theory of Antibiotic Resistance

The evolutionary theory of antibiotic resistance is based on principles established by Charles Darwin in his theory of evolution by natural selection. This theory posits that antibiotic resistance arises through the process of natural selection acting on genetic variation within bacterial populations. Bacteria with mutations conferring resistance to antibiotics have a survival advantage when exposed to these drugs, allowing them to proliferate and pass on their resistance genes to future generations. Over time, this selective pressure drives the emergence and spread of antibiotic-resistant strains. Understanding the evolutionary dynamics of antibiotic resistance is crucial for developing effective strategies to combat it. By elucidating how resistance evolves and spreads within bacterial populations, researchers can identify potential targets for intervention, such as disrupting resistance mechanisms or reducing the selective pressure of antibiotics (Hughes and Andersson, 2017).

Game Theory in Antibiotic Stewardship

Game theory principles have been applied to antibiotic resistance research by scholars such as Martin A. Nowak and Robert M. May. Game theory provides a framework for analyzing strategic interactions between individuals or groups with conflicting interests. In the context of antibiotic resistance, this theory models the interactions between bacteria, healthcare providers, and patients regarding antibiotic use. It explores how different strategies, such as overuse or appropriate use of antibiotics, influence the spread of resistance and the overall effectiveness of antibiotic treatment. Applying game theory to antibiotic stewardship can help optimize decision-making processes and develop more effective policies for controlling antibiotic resistance. By considering the incentives and motivations of various stakeholders, researchers can design interventions that promote responsible antibiotic use while minimizing the risk of resistance emergence (Olesen, 2018).

Empirical Review

Blair (2016) investigated the role of efflux pumps in antibiotic resistance mechanisms in Gram-negative bacteria. Utilized genetic knockout mutants and efflux pump inhibitors to elucidate the contribution of efflux pumps to antibiotic resistance. Efflux pumps significantly contribute to antibiotic resistance by actively expelling antibiotics from bacterial cells, reducing intracellular drug concentrations. Targeting efflux pumps could enhance the efficacy of existing antibiotics and combat multidrug resistance.

Pitout (2015) assessed the prevalence and mechanisms of carbapenem resistance in clinical isolates of Enterobacteriaceae. Conducted phenotypic and genotypic characterization of carbapenem-resistant strains, including whole-genome sequencing and plasmid analysis. Identified the widespread dissemination of carbapenemase-producing Enterobacteriaceae, with diverse genetic determinants contributing to resistance. Implement stringent infection control measures and surveillance to prevent the spread of carbapenem-resistant strains.

Drawz (2010) assessed the efficacy of combination therapy with β-lactam antibiotics and β-lactamase inhibitors in combating resistance in Gram-negative bacteria. Conducted in vitro susceptibility testing and time-kill assays to evaluate the synergistic effects of β-lactam/β-lactamase inhibitor combinations. Combination therapy restored the activity of β-lactam antibiotics against β-lactamase-producing Gram-negative bacteria, overcoming resistance. Promote the use of combination therapy as a strategy to enhance the efficacy of β-lactam antibiotics and combat resistance.

San Millan (2018) investigated the role of mobile genetic elements (MGEs) in the dissemination of antibiotic resistance genes among bacterial populations. Utilized high-throughput sequencing and comparative genomics to analyze the diversity and dynamics of MGEs carrying antibiotic resistance genes. MGEs play a crucial role in facilitating the horizontal transfer of antibiotic resistance genes between bacterial species, contributing to the spread of resistance. Targeting MGEs and their transfer mechanisms could provide new avenues for intervention to prevent the dissemination of antibiotic resistance.

Lázár(2014) investigated the impact of antibiotic combination therapy on the evolution of resistance in Pseudomonas aeruginosa infections. Conducted in vitro evolution experiments exposing P. aeruginosa to single vs. combination antibiotic therapy, followed by whole-genome sequencing. Combination therapy delayed the emergence of resistance compared to monotherapy by targeting multiple resistance mechanisms simultaneously. Consider combination therapy as a strategy to prolong the effectiveness of antibiotics and minimize the development of resistance.

Schuts (2016) evaluated the effectiveness of antimicrobial stewardship programs in reducing antibiotic resistance in healthcare settings. Conducted a systematic review and meta-analysis of studies assessing the impact of stewardship interventions on antibiotic prescribing and resistance rates. Antimicrobial stewardship programs were associated with reductions in antibiotic consumption and resistance rates across various healthcare settings. Advocate for the implementation of comprehensive stewardship programs as a key strategy to combat antibiotic resistance.

McVay(2017) explored the potential of bacteriophage therapy as an alternative treatment for antibiotic-resistant bacterial infections. Conducted clinical trials evaluating the safety and efficacy of bacteriophage therapy in patients with multidrug-resistant bacterial infections. Bacteriophage therapy demonstrated promising results in treating antibiotic-resistant infections, with minimal adverse effects. Further research and clinical trials are warranted to establish the efficacy and safety of bacteriophage therapy as a mainstream treatment option.

International Journal of Biology

ISSN 2710-3765 (Online)
Vol 4, Issue 1, No.4, pp 35 - 45, 2024

www.iprjb.org

METHODOLOGY

This study adopted a desk methodology. A desk study research design is commonly known as secondary data collection. This is basically collecting data from existing resources preferably because of its low cost advantage as compared to a field research. Our current study looked into already published studies and reports as the data was easily accessed through online journals and libraries

RESULTS

Conceptual Gaps

Blair (2016) investigated the role of efflux pumps in antibiotic resistance, there remains a conceptual gap in understanding the precise mechanisms of efflux pump inhibition and its potential as a therapeutic strategy. Drawz (2010) assessed the efficacy of combination therapy in combating resistance in Gram-negative bacteria. However, there's a conceptual gap in understanding the long-term evolutionary consequences of combination therapy on the development of resistance. San Millan (2018) investigated the role of MGEs in disseminating antibiotic resistance genes. However, there's a conceptual gap in the development of intervention strategies specifically targeting MGEs to prevent horizontal gene transfer.

Contextual Gaps

Pitout (2015) assessed the prevalence and mechanisms of carbapenem resistance in clinical isolates of Enterobacteriaceae. However, there's a contextual gap in understanding the clinical impact of carbapenem resistance on patient outcomes, healthcare costs, and treatment strategies. Schuts (2016) evaluated the effectiveness of antimicrobial stewardship programs in reducing antibiotic resistance. However, there's a contextual gap in understanding the specific components and implementation strategies that contribute to the success of stewardship programs across diverse healthcare settings.

Geographical Gaps

McVay (2017) explored the potential of bacteriophage therapy as an alternative treatment for antibiotic-resistant bacterial infections. However, there's a geographical gap in understanding the generalizability of bacteriophage therapy across different regions with varying bacterial resistance profiles and healthcare infrastructures.

CONCLUSION AND RECOMMENDATIONS

Conclusion

In conclusion, antibiotic resistance represents a complex and evolving challenge to global public health. Mechanisms such as efflux pumps, mobile genetic elements, and enzymatic degradation contribute to the resilience of bacteria against antibiotics. However, strategic interventions have been identified to combat resistance effectively. Exploration of alternative therapies like bacteriophage therapy offers promising avenues for addressing antibiotic-resistant infections, especially in light of increasing resistance rates. However, addressing antibiotic resistance requires a multifaceted approach that goes beyond the laboratory. It involves implementing policies to regulate antibiotic use in healthcare settings and agriculture, promoting public education on the responsible use of antibiotics, and investing in the development of novel antimicrobial agents and alternative treatment modalities.

Recommendations

Theory

Invest in Basic Research: Allocate funding for basic research aimed at elucidating novel antibiotic resistance mechanisms, including genetic determinants, molecular pathways, and microbial interactions. This theoretical understanding will provide a foundation for developing innovative therapeutic approaches.

Enhance Surveillance Systems: Strengthen global surveillance networks to monitor the emergence and spread of antibiotic-resistant pathogens. Utilize advanced genomic and bioinformatic tools to track resistance genes, genetic elements, and transmission patterns, contributing to a deeper theoretical understanding of resistance dynamics.

Practice

Promote Antibiotic Stewardship: Implement antimicrobial stewardship programs across healthcare settings to optimize antibiotic use. These programs should involve prescriber education, antibiotic guidelines, and regular audits to promote appropriate prescribing practices and minimize unnecessary antibiotic exposure.

Encourage Multidisciplinary Collaboration: Foster collaboration between clinicians, microbiologists, pharmacologists, epidemiologists, and other stakeholders to develop comprehensive strategies for managing antibiotic resistance. This interdisciplinary approach can facilitate the translation of theoretical insights into practical interventions tailored to specific clinical contexts.

Emphasize Infection Prevention: Prioritize infection prevention measures, including hand hygiene, environmental cleaning, and infection control protocols, to reduce the spread of resistant pathogens within healthcare facilities and communities. Combining theoretical knowledge of resistance mechanisms with practical infection control strategies can mitigate the transmission of resistant strains.

Policy

Implement Regulatory Measures: Enact policies to regulate the use of antibiotics in human health, veterinary medicine, and agriculture. This includes restrictions on antibiotic use in food production, bans on over-the-counter antibiotic sales, and incentives for the development of new antibiotics.

Support Research and Development: Allocate government funding and establish public-private partnerships to incentivize the development of novel antimicrobial agents, diagnostics, and alternative therapies. Policy initiatives such as research grants, tax incentives, and regulatory fast-tracking can stimulate innovation in the field of antibiotic discovery.

Global Cooperation: Foster international collaboration and information sharing to address antibiotic resistance as a global health priority. Establishing frameworks for data exchange, harmonizing antimicrobial resistance surveillance protocols, and coordinating research efforts can amplify the impact of individual national policies and initiatives.

REFERENCES

Allegranzi, B., Bagheri Nejad, S., Combescure, C., Graafmans, W., Attar, H., Donaldson, L., ... Pittet, D. (2011). Burden of Endemic Health-Care-Associated Infection in Developing Countries: Systematic Review and Meta-analysis. The Lancet, 377(9761), 228–241.

Blair, J. M., & Piddock, L. J. (2016). "How to measure export via bacterial multidrug resistance efflux pumps." mBio, 7(4), e00840-16.

CDC. (2013). Vital signs: Carbapenem-resistant Enterobacteriaceae. Centers for Disease Control and Prevention. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6210a3.htm

CDC. (2019). Antibiotic Resistance Threats in the United States, 2019. Centers for Disease Control and Prevention. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf

Dalal, A., Pawaskar, A., Das, M., Desai, R., Prabhudesai, P., Chhajed, P., ... Mathuria, J. P. (2016). High Prevalence of Extensively Drug-Resistant Tuberculosis among Patients with Multidrug-Resistant Tuberculosis in a Tertiary Care Hospital in Mumbai, India. PLOS ONE, 11(1), e0147575. https://doi.org/10.1371/journal.pone.0147575

Drawz, S. M., & Bonomo, R. A. (2010). "Three decades of β-lactamase inhibitors." Clinical Microbiology Reviews, 23(1), 160-201.

Golkar, Z., Bagasra, O., & Pace, D. G. (2014). Bacteriophage Therapy: A Potential Solution for the Antibiotic Resistance Crisis. Journal of Infection in Developing Countries, 8(2), 129–136.

Hughes, D., & Andersson, D. I. (2017). Environmental and Genetic Modulation of the Phenotypic Expression of Antibiotic Resistance. Frontiers in Microbiology, 8, 9. https://doi.org/10.3389/fmicb.2017.00009

Johnson, J. R., Porter, S. B., Thuras, P., Castanheira, M., & Sader, H. S. (2017). Epidemic emergence in the United States of Escherichia coli sequence type 131-H30 (ST131-H30), 2000 to 2009. Antimicrobial Agents and Chemotherapy, 61(6), e00732-17. https://doi.org/10.1128/AAC.00732-17

Jones, R. N., Guzman-Blanco, M., Gales, A. C., Gallegos, B., Castro, A. L., & Martino, M. D. V. (2015). Susceptibility Rates in Latin American Nations: Report from a Regional Resistance

Kariuki, S., Onsare, R. S., Damjanova, I., & Keddy, K. H. (2015). Challenges and Perspectives for Monitoring Antimicrobial Drug Resistance in Salmonella in Low-Resource Settings. BMC Proceedings, 9(Suppl 10), S7. https://doi.org/10.1186/1753-6561-9-S10-S7

Krumkamp, R., Sarpong, N., Schwarz, N. G., Adlkofer, J., Loag, W., Eibach, D., ... May, J. (2015). Gastrointestinal Infections and Diarrheal Disease in Ghanaian Infants and Children: An Outpatient Case-Control Study. PLOS Neglected Tropical Diseases, 9(3), e0003568. https://doi.org/10.1371/journal.pntd.0003568

Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., ... Cars, O. (2013). Antibiotic Resistance—the Need for Global Solutions. The Lancet Infectious Diseases, 13(12), 1057–1098.

Lázár, V. (2014). "Bacterial evolution of antibiotic hypersensitivity." Molecular Systems Biology, 9(1), 700.

Martins, N., Picão, R. C., Cerqueira-Alves, M., & Gales, A. C. (2018). Acinetobacter baumannii in Brazil: emergence of highly resistant bacteria in a high-risk hospital setting. Infection Control & Hospital Epidemiology, 39(8), 988–989. https://doi.org/10.1017/ice.2018.143

McVay, C. S. (2017). "Bacteriophage therapy for bacterial infections: Not a 'last resort' treatment option." Clinical Microbiology and Infection, 23(9), 681-688.

Olesen, S. W., Barnett, M. L., MacFadden, D. R., & Lipsitch, M. (2018). Modeling the Impact of Interventions on an Epidemic of Clostridium difficile Infections in Hospitals. Clinical Infectious Diseases, 66(11), 1729–1737. https://doi.org/10.1093/cid/cix1112

Olowe, O. A., Taiwo, S. S., Onile-ere, O. A., & Ojurongbe, O. (2017). Prevalence of Extended-Spectrum β-Lactamase and Plasmid-Mediated Quinolone Resistance Genes in Escherichia coli and Klebsiella pneumoniae Isolated from Clinical Samples in Ogbomoso, Nigeria. Advances in Medicine, 2017, 1–6. https://doi.org/10.1155/2017/1046493

Olowe, O. A., Taiwo, S. S., Onile-ere, O. A., & Ojurongbe, O. (2017). Prevalence of Extended-Spectrum β-Lactamase and Plasmid-Mediated Quinolone Resistance Genes in Escherichia coli and Klebsiella pneumoniae Isolated from Clinical Samples in Ogbomoso, Nigeria. Advances in Medicine, 2017, 1–6. https://doi.org/10.1155/2017/1046493

PHE. (2019). English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report 2019 to 2020. Public Health England. https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report

Pitout, J. D., & Nordmann, P. (2015). "Poirel Carbapenemase-Producing Enterobacteriaceae: A Review of Key Epidemiological and Resistance Trends." Microbiology Spectrum, 3(6).

Said, H. M., Kock, M. M., Ismail, N. A., Mphahlele, M., Baba, K., Omar, S. V., … Wainwright, H. (2018). Evolution of extensively drug-resistant tuberculosis over four decades: whole genome sequencing and dating analysis of Mycobacterium tuberculosis isolates from KwaZulu-Natal. PLOS ONE, 13(10), e0206657. https://doi.org/10.1371/journal.pone.0206657

San Millan, A. (2018). "Evolution of plasmid-mediated antibiotic resistance in the clinical context." Trends in Microbiology, 26(12), 978-985.

Schuts, E. C. (2016). "Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis." The Lancet Infectious Diseases, 16(7), 847-856.

Surveillance Program (2011). Diagnostic Microbiology and Infectious Disease, 83(2), 242–247. https://doi.org/10.1016/j.diagmicrobio.2015.07.012

Tadesse, M., Aragaw, D., Dimah, B., Efa, F., Abdella, K., Kebede, W., ... Gebeyehu, M. (2017). Drug resistance-conferring mutations in Mycobacterium tuberculosis from pulmonary tuberculosis patients in Southwest Ethiopia. International Journal of Mycobacteriology, 6(4), 361–366. https://doi.org/10.4103/ijmy.ijmy_127_17

Takizawa, Y., Taneike, I., Nakagawa, S., Oishi, T., Nitahara, Y., Iwakura, N., … Hiramatsu, K. (2013). A Panton-Valentine Leukocidin (PVL)-Positive Community-acquired Methicillin-resistant Staphylococcus aureus (MRSA) Strain, Another such Strain carrying a Multiple-drug Resistance Plasmid, and other more-typical PVL-negative MRSA Strains found in Japan. Journal of Infection and Chemotherapy, 19(3), 395–404. https://doi.org/10.1007/s10156-012-0505-x

Ventola, C. L. (2015). The Antibiotic Resistance Crisis: Part 1: Causes and Threats. Pharmacy and Therapeutics, 40(4), 277–283.

World Health Organization. (2019). Global Action Plan on Antimicrobial Resistance. https://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/